Effective dose assessment in body organs after injection of 131I-MIBG
نویسندگان
چکیده مقاله:
Introduction: Development of a novel radiopharmaceutical needs assessment of its biological- distribution in animal models, most commonly mice prior to its common application. This study describes the biodistribution and absorbed dose prediction 131I-MIBG in human organs after injection in mice. Materials and Methods: In this research, 131I-MIBG radiopharmaceutical was injected to mice. After 4, 12, 24, and 48 hours post injection, the mice sacrificed and its organs dissected and counted by well detector. Then with having the Injected dose per gram of organs, absorbed dose of organs was calculated by MCNP simulation code and MIRD methods. Results: The results showed that the intestine and thyroid organs absorbed the least and most dose after injection of 131I-MIBG in mice. Conclusion: Many studies have demonstrated the usefulness of using animal distribution as a model for absorbed dose estimations in humans. Radiation dosimetry for 131I-MIBG was estimated for humans based on the biodistribution data in normal mice. The obtained results by MIRD and MCNP had shown close results.
منابع مشابه
Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
BACKGROUND (131)I Metaiodobenzylguanidine ((131)I-MIBG) is an effective targeted radiotherapeutic for neuroblastoma with response rates greater than 30% in refractory disease. Toxicity is mainly limited to myelosuppression. The aim of this study was to determine the response rate and hematologic toxicity of multiple infusions of (131)I-MIBG. PROCEDURE Patients received two to four infusions o...
متن کاملWhole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
UNLABELLED The aims of this study were to examine the relationship between whole-body absorbed dose and hematologic toxicity and to assess the most accurate method of delivering a prescribed whole-body absorbed dose in (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for neuroblastoma. METHODS A total of 20 children (1-12 y), 5 adolescents (13-17 y), and 1 adult (20 y) with stage 3 or 4 n...
متن کامل131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
OBJECTIVE Neuroblastoma is the third most common malignancy of childhood. 131I-MIBG scintigraphy must be performed in patients with neuroblastoma at the time of staging. The aim of this study is to identify the role of 131I-MIBG scintigraphy in neuroblastoma patients in correlation with other diagnostic modalities for staging of the disease. METHODS Twenty six patients provisionally diagnosed...
متن کاملEnhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
UNLABELLED 131I-labeled metaiodobenzylguanidine (MIBG) is an established treatment modality for neuroendocrine tumors. Because of low tumor doses, it has a predominantly palliative character. Our approach was to investigate whether intraarterial application of 131I-MIBG has the potential to enhance tumor uptake. METHODS Seventeen patients with primary or metastasized neuroendocrine tumors rec...
متن کامل131I-MIBG imaging in evaluation of neuro-endocrine (APUD) tumors [Persian]
In this study, l-131-MIBG imaging was performed in 44 patients with clinical suspicion of tumors originating from neuro-endocrine system. The patients were referred to our department following plasma and urinary measurement of epinephrine, norepinehrine and vanilmandelic acidfVMA). Radionuclide imaging was performel as a comparative or confirmatory measure in all patients who had previous...
متن کاملFeasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol
Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ذخیره در منابع من قبلا به منابع من ذحیره شده{@ msg_add @}
عنوان ژورنال
دوره 15 شماره Special Issue-12th. Iranian Congress of Medical Physics
صفحات 440- 440
تاریخ انتشار 2018-12-01
با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023